JP7538724B2 - 細胞保護の方法と組成物 - Google Patents

細胞保護の方法と組成物 Download PDF

Info

Publication number
JP7538724B2
JP7538724B2 JP2020570916A JP2020570916A JP7538724B2 JP 7538724 B2 JP7538724 B2 JP 7538724B2 JP 2020570916 A JP2020570916 A JP 2020570916A JP 2020570916 A JP2020570916 A JP 2020570916A JP 7538724 B2 JP7538724 B2 JP 7538724B2
Authority
JP
Japan
Prior art keywords
mer
groups
chondroitin sulfate
group
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020570916A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021528421A5 (https=
JP2021528421A (ja
Inventor
リュー ジアン
リ ジン
ス グオウェイ
パウリンスキー ラファル
スパーケンバウ エリカ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Publication of JP2021528421A publication Critical patent/JP2021528421A/ja
Publication of JP2021528421A5 publication Critical patent/JP2021528421A5/ja
Application granted granted Critical
Publication of JP7538724B2 publication Critical patent/JP7538724B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020570916A 2018-06-20 2019-06-19 細胞保護の方法と組成物 Active JP7538724B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862687540P 2018-06-20 2018-06-20
US62/687,540 2018-06-20
PCT/US2019/037993 WO2019246264A1 (en) 2018-06-20 2019-06-19 Cell protective methods and compositions

Publications (3)

Publication Number Publication Date
JP2021528421A JP2021528421A (ja) 2021-10-21
JP2021528421A5 JP2021528421A5 (https=) 2022-06-27
JP7538724B2 true JP7538724B2 (ja) 2024-08-22

Family

ID=68984366

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020570916A Active JP7538724B2 (ja) 2018-06-20 2019-06-19 細胞保護の方法と組成物

Country Status (5)

Country Link
US (2) US11633424B2 (https=)
EP (1) EP3810152A4 (https=)
JP (1) JP7538724B2 (https=)
CN (1) CN112437667B (https=)
WO (1) WO2019246264A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12397016B2 (en) 2017-11-03 2025-08-26 The University Of North Carolina At Chapel Hill Sulfated oligosaccharides having anti-inflammatory activity
US12539311B2 (en) 2017-03-10 2026-02-03 The University Of North Carolina At Chapel Hill Short-acting heparin-based anticoagulant compounds and methods
US12569512B2 (en) 2019-11-13 2026-03-10 The University Of North Carolina At Chapel Hill Heparan sulfate (HS) oligosaccharides effect in liver ischemia reperfusion injury

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11993627B2 (en) * 2017-07-03 2024-05-28 The University Of North Carolina At Chapel Hill Enzymatic synthesis of homogeneous chondroitin sulfate oligosaccharides
CN116254296A (zh) * 2023-03-27 2023-06-13 中国科学院微生物研究所 利用昆虫细胞杆状病毒表达系统表达硫酸软骨素修饰酶的方法及应用
CN116254295A (zh) * 2023-03-27 2023-06-13 中国科学院微生物研究所 利用昆虫细胞杆状病毒表达系统表达软骨素6-o-硫酸转移酶的方法及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060229276A1 (en) 2004-07-28 2006-10-12 Magnus Hook Use of glycosoaminoglycans for the prevention and treatment of sepsis

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
IT1232939B (it) 1987-11-06 1992-03-10 Opocrin Spa Eparan solfato caratterizzato da elevata attivita' antitrombotica, elevata biodisponibilita', assenza di attivita' anticoagulante; suo processo di estrazione da organi e da tessuti e relative composizioni farmaceutiche
US4865870A (en) 1988-07-07 1989-09-12 Becton, Dickinson And Company Method for rendering a substrate surface antithrombogenic
PT93847A (pt) 1989-04-24 1990-11-20 Harvard College Processo para a preparacao de oligossacaridos de baixo peso molecular derivados de heparina ou de sulfato de heparano despolimerizados e de composicoes farmaceuticas que os contem
US5378829A (en) 1990-04-23 1995-01-03 Akzo N.V. Sulfated glycosaminoglycanoid derivatives of the heparin and heparan sulfate type
WO1993005167A1 (en) 1991-09-06 1993-03-18 Children's Medical Center Corporation Cell-type specific heparan sulfate proteoglycans and their uses
IT1260137B (it) 1992-04-17 1996-03-28 Alfa Wassermann Spa Glicosaminoglicani semisintetici a struttura eparinica od eparanica modificati nella posizione 2 dell'acido alfa-l-iduronico-2-0-solfato
JP3818676B2 (ja) 1994-07-22 2006-09-06 生化学工業株式会社 ヘパラン硫酸６−ｏ−硫酸基転移酵素
IT1271057B (it) 1994-11-04 1997-05-26 Inalco Spa Polisaccaridi aventi un elevato contenuto di acido iduronico
JP3672359B2 (ja) 1995-07-24 2005-07-20 生化学工業株式会社 ヘパラン硫酸 ２−ｏ−硫酸基転移酵素
DK0852491T3 (da) 1995-09-29 2004-12-20 Biomarin Pharm Inc Anvendelse af heparinaser til at mindske inflammatoriske responser
US5935824A (en) 1996-01-31 1999-08-10 Technologene, Inc. Protein expression system
US6861254B1 (en) 1997-10-24 2005-03-01 Massachusetts Institute Of Technology Heparan sulfate D-glucosaminyl 3-O-sulfotransferases, and uses therefor
US8088604B2 (en) 1998-04-02 2012-01-03 The Board Of Regents Of The University Of Oklahoma Production of defined monodisperse heparosan polymers and unnatural polymers with polysaccharide synthases
US7307159B2 (en) 2001-05-08 2007-12-11 The Board Of Regents Of The University Of Oklahoma Heparin/heparosan synthase from P. multocida and methods of making and using same
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
US6255088B1 (en) 1999-05-11 2001-07-03 The Scripps Research Institute Enzymatic sulfation of biomolecules
US7101859B2 (en) * 2000-01-10 2006-09-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases
DE60140941D1 (de) 2000-07-07 2010-02-11 Seikagaku Kogyo Co Ltd Hyaluronsäure oligosaccharid fraktionen und medikamente, die diese enthalten
US8067196B2 (en) 2001-03-28 2011-11-29 Massachusetts Institute Of Technology 6-O sulfated polysaccharides and methods of preparation thereof
DK2070939T3 (da) 2001-05-25 2014-06-23 Univ Duke Modulatorer af farmakologiske midler
WO2003018598A2 (en) 2001-08-30 2003-03-06 University College Dublin Monosaccharide derivatives
AU2003247808A1 (en) 2002-07-05 2004-01-23 Anders Malmstrom Purified and isolated heparan sulfate 3-o-sulfotransferase isoform 5 nucleic acids and polypeptides and therapeutic and screening methods using same
GB0216861D0 (en) 2002-07-19 2002-08-28 Univ Birmingham Saccharide libraries
AU2003262794A1 (en) 2002-08-23 2004-03-11 Neose Technologies, Inc. Total synthesis of heparin
WO2005014619A2 (en) 2003-03-28 2005-02-17 Thomas Jefferson University Heparin-binding peptides and uses thereof
DE60336400D1 (de) 2003-10-24 2011-04-28 3M Innovative Properties Co Wässrige Dispersionen von Polytetrafluorethylenteilchen
US7655445B2 (en) 2003-11-12 2010-02-02 Massachusetts Institute Of Technology Methods for synthesis of sulfated saccharides
US7638503B2 (en) * 2004-05-26 2009-12-29 California Institute Of Technology Small molecule stimulators of neuronal growth
EP1885865A4 (en) 2005-05-12 2010-12-22 Univ North Carolina ENZYMATIC SYNTHESIS OF SULFATED POLYSACCHARIDES
EP2447285A3 (en) 2006-05-25 2013-01-16 Momenta Pharmaceuticals, Inc. Low molecular weight heparin composition and uses thereof
WO2009014715A2 (en) 2007-07-23 2009-01-29 The University Of North Carolina At Chapel Hill Enzymatic synthesis of sulfated polysaccharides without iduronic acid residues
ES2567079T3 (es) 2007-11-02 2016-04-19 Momenta Pharmaceuticals, Inc. Composiciones de polisacáridos que no son anticoagulantes
MX2011004907A (es) 2008-11-14 2011-07-29 Portola Pharm Inc Antidotos para inhibidores del factor xa y metodos para el uso de los mismos en combinacion con agentes de coagulacion de sangre.
BRPI1007325A2 (pt) * 2009-02-02 2019-09-24 Otsuka Pharma Co Ltd "baixo peso molecular de polissulfatados derivados de ácido hialurônico e medicamentos que contenham o mesmo."
AU2010233151A1 (en) 2009-04-09 2011-11-17 The University Of North Carolina At Chapel Hill Methods of treating edema related to ischemia-reperfusion
US20110054236A1 (en) 2009-08-25 2011-03-03 The Regents Of The University Of Michigan Compositions and methods for targeting tumors
US20120322760A1 (en) 2009-09-23 2012-12-20 Momenta Pharmaceuticals, Inc. Methods of treatment with a low molecular weight heparin composition
JP2014501730A (ja) * 2010-12-01 2014-01-23 ジ オーストラリアン ナショナル ユニバーシティ ヒストン阻害
WO2012088416A2 (en) 2010-12-23 2012-06-28 The University Of North Carolina At Chapel Hill Chemoenzymatic synthesis of structurally homogeneous ultra-low molecular weight heparins
WO2012116048A1 (en) 2011-02-22 2012-08-30 Rensselaer Polytechnic Institute Single step heparosan n-deacetylation and depolymerization for making bioengineered heparin
WO2012162789A1 (en) 2011-06-01 2012-12-06 University Of British Columbia Polymers for reversing heparin-based anticoagulation
CN105188750A (zh) 2013-03-08 2015-12-23 德国杰特贝林生物制品有限公司 治疗和预防远端缺血-再灌注损伤
JP6670235B2 (ja) 2013-06-17 2020-03-18 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｃａｒｏｌｉｎａ Ａｔ Ｃｈａｐｅｌ Ｈｉｌｌ 可逆的ヘパリン分子、その製法及びその使用方法
CN116622006B (zh) 2017-03-10 2025-05-30 北卡罗来纳大学查珀尔希尔分校 短效的基于肝素的抗凝血剂化合物和方法
US11993627B2 (en) * 2017-07-03 2024-05-28 The University Of North Carolina At Chapel Hill Enzymatic synthesis of homogeneous chondroitin sulfate oligosaccharides
JP7495061B2 (ja) 2017-11-03 2024-06-04 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 抗炎症作用を有する硫酸化オリゴ糖
JP7801217B2 (ja) 2019-11-13 2026-01-16 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 肝虚血再灌流障害におけるヘパラン硫酸（ｈｓ）オリゴ糖の効果

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060229276A1 (en) 2004-07-28 2006-10-12 Magnus Hook Use of glycosoaminoglycans for the prevention and treatment of sepsis

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Angew. Chem.，2017年，Vol.129，pp.11946-11949
Biomaterials，2013年，Vol.34，pp.5670-5676
Critical Care，2008年，Vol.12，Article No.R86
European Journal of Pharmacology，2018年03月，Vol.826，pp.48-55
J. Microwave Surg.，2006年，Vol.24，pp.19-26

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12539311B2 (en) 2017-03-10 2026-02-03 The University Of North Carolina At Chapel Hill Short-acting heparin-based anticoagulant compounds and methods
US12397016B2 (en) 2017-11-03 2025-08-26 The University Of North Carolina At Chapel Hill Sulfated oligosaccharides having anti-inflammatory activity
US12569512B2 (en) 2019-11-13 2026-03-10 The University Of North Carolina At Chapel Hill Heparan sulfate (HS) oligosaccharides effect in liver ischemia reperfusion injury

Also Published As

Publication number Publication date
CN112437667A (zh) 2021-03-02
US20210260098A1 (en) 2021-08-26
US11633424B2 (en) 2023-04-25
EP3810152A4 (en) 2022-04-27
CN112437667B (zh) 2024-05-28
JP2021528421A (ja) 2021-10-21
EP3810152A1 (en) 2021-04-28
US20230277580A1 (en) 2023-09-07
WO2019246264A1 (en) 2019-12-26

Similar Documents

Publication Publication Date Title
JP7538724B2 (ja) 細胞保護の方法と組成物
JP2806454B2 (ja) 脈管形成阻止剤
US12539311B2 (en) Short-acting heparin-based anticoagulant compounds and methods
US6943190B2 (en) Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions
JP4536918B2 (ja) 免疫調整機能を有するγ−グルタミルとβ−アスパルチル化合物および免疫調節剤
JPH0456805B2 (https=)
CN103402526B (zh) 组蛋白抑制
CN114980904A (zh) 硫酸乙酰肝素(hs)低聚糖在肝缺血再灌注损伤中的影响
EP1082963A1 (en) Remedies for joint diseases bound to hyaluronic acid
CA2377904C (en) Medicament with a protective effect against oxidative-toxic substances, particularly against cardiotoxic substances
Teitz et al. The effect of salicylate and chloroquine on prostaglandin-induced articular damage in the rabbit knee
CN102458113A (zh) 与缺血再灌注相关的水肿的治疗方法
BG65681B1 (bg) Средство за лечение на болести на ставите
WO2022184091A1 (zh) 透明质酸在用于制备预防或治疗铁死亡相关疾病的药物中的应用
PT1853279E (pt) Derivados de amida de ácido hialurónico para osteoartrose
Weisberger et al. Some structural requirements for the prevention of leukopenia induced by nitrogen mustard
WO2025137542A1 (en) Use of heparan sulfate (hs) oligosaccharides in diseases
JP6444399B2 (ja) 癌の処置に用いるための硫酸化多糖
WO2005089068A2 (en) Pharmaceutical compositions comprising anti-inflammatory quinazolinecarboxamide derivatives
JP2009534383A (ja) 黒色腫の治療
Harris et al. Diet-induced protection against lipopolysaccharide includes increased hepatic NO production
RU2814013C1 (ru) Способ использования 4-((5,10-диметил-6-оксо-6,10-дигидро-5Н-пиримидо[5,4-b]тиено[3,2-e][1,4]диазепин-2-ил)амино)бензолсульфонамида (XMU-MP-1) для подавления роста клеток лимфомы Беркитта
JPH02256610A (ja) ポリアロマティック化合物を含有する医薬用組成物
JPH02209807A (ja) 抗炎症剤
Bannerman Mechanisms of endotoxin-induced endothelial monolayer disruption: Roles of tyrosine phosphorylation, caspase activation, and the actin-associated adherens junctions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220617

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220617

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20230227

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230421

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230620

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230919

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240415

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240716

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240809

R150 Certificate of patent or registration of utility model

Ref document number: 7538724

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150